Safety and Efficacy of Rituximab for Treatment of Multicentric Castleman Disease in Malawi
Status:
Recruiting
Trial end date:
2026-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the safety and efficacy of first-line,
risk-stratified Rituximab-based Multicentric Castleman Disease (MCD) treatment in Malawi in a
single-arm, phase II clinical trial. This study also aims to compare the cost-effectiveness
of first-line Rituximab treatment for MCD in Malawi to chemotherapy.
Phase:
Phase 2
Details
Lead Sponsor:
UNC Lineberger Comprehensive Cancer Center
Collaborator:
Fogarty International Center of the National Institute of Health